Quanterix Corp. (QTRX) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three and nine months ended September 30, 2025. Quanterix Corporation is a life sciences company developing ultra-sensitive digital immunoassay platforms (Simoa) and, following the July 2025 acquisition of Akoya Biosciences, Inc., spatial biology solutions. The company operates as a single reportable segment focused on protein biomarker solutions for research and diagnostics.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 |
|---|---|---|
| Total Revenues | $40.2 million | $95.0 million |
| Gross Profit | $17.2 million (43% margin) | $44.9 million (47% margin) |
| Net Loss | $(33.5) million | $(84.0) million |
| Net Loss Per Share (Basic/Diluted) | $(0.73) | $(2.04) |
| Cash, Cash Equivalents, and Marketable Securities | $134.8 million (as of Sept 30, 2025) | N/A |
| Net Cash Used in Operating Activities | N/A | $(60.8) million |
| Accumulated Deficit | $(554.1) million | N/A |
Material Changes vs. Prior Period
- Acquisitions: The company completed the acquisition of Akoya Biosciences, Inc. on July 8, 2025, for a total consideration of approximately $151.0 million (including debt repayment). This added $17.2 million in revenue and $8.4 million to the net loss for the quarter. The company also acquired Emission, Inc. in January 2025.
- Revenue Mix: Product revenue increased 33% year-over-year (Q3) driven by Akoya, while legacy Quanterix product revenue declined 25% due to reduced federal research funding and macroeconomic headwinds. Service revenue remained relatively flat overall but declined 42% in the legacy business.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses surged 71% in Q3 to $39.1 million, driven by $7.4 million in Akoya-related costs and $4.7 million in non-recurring acquisition and integration costs.
- Impairments and Restructuring: The company recorded $7.2 million in impairment and restructuring costs in Q3, including $0.9 million for an impaired leased facility and severance costs. A full goodwill impairment of $6.4 million was recorded in Q2 2025 related to the Emission acquisition.
- Liquidity: Cash and marketable securities decreased from $289.1 million at year-end 2024 to $134.8 million at September 30, 2025, primarily due to acquisition payments and operating losses.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur operating losses into 2026. However, they project the combined company will achieve cash flow breakeven in 2026, contingent on meeting revenue and expense objectives following integration synergies.
- Restructuring: Actions taken in May and July 2025 are expected to reduce annualized operating expenses by approximately $67.0 million, with a goal of $85.0 million in total reductions by early 2026.
- Internal Controls: The company disclosed that its internal control over financial reporting was not effective as of September 30, 2025, due to material weaknesses in inventory valuation and the accounting for Accelerator Laboratory revenue. Remediation efforts are ongoing.
- Risks: Key risks include the successful integration of Akoya, potential failure to realize synergies, continued softness in instrument sales due to constrained capital funding, and regulatory uncertainties regarding FDA oversight of Laboratory Developed Tests (LDTs).
Investor Verification Checklist
- Internal Control Remediation: Verify the progress and timeline for remediation of the material weaknesses in inventory valuation and revenue recognition.
- Integration Synergies: Monitor the realization of the projected $67 million to $85 million in annualized cost savings from the Akoya integration.
- Legacy Revenue Trends: Assess the sustainability of the decline in legacy Quanterix revenue amidst reduced federal research funding.
- Capital Requirements: Evaluate the sufficiency of the $134.8 million cash position to fund operations through 2026 without additional dilutive financing.
- Regulatory Status: Track the FDA's evolving stance on LDTs and its potential impact on the company's diagnostic services revenue.